Table 3 Hazard ratio of overall survival in melanoma patients based on age at diagnosis of melanoma and interval from first melanoma to specific SPC diagnosis
From: Types of second primary cancer influence overall survival in cutaneous melanoma
Age at diagnosis (years old) | No SPC | Interval to SPC from first melanoma diagnosis | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
< 1 year | 1–5 year | 6–10 year | > 10 year | |||||||
N | HR (95% CI) | N | HR (95% CI) | N | HR (95% CI) | N | HR (95% CI) | N | HR (95% CI) | |
Squamous cell skin cancer | ||||||||||
< 60 | 2144 | Reference | 2 | 2.1 (0.6–6.5) | 6 | 1.7 (0. 8–3.7) | 8 | 1.0 (0.52–2.0) | 7 | 0.2 (0.1–0.5) |
60–79 | 5251 | 3.9 (3.7–4.1) | 22 | 6.7 (4.5–10.0) | 75 | 5.7 (4. 6–7.1) | 62 | 6.5 (5.0–8.3) | 50 | 6.8 (5.1–9.1) |
≥ 80 | 3641 | 15.7 (14.8–16.6) | 42 | 20.0 (14.9–26.7) | 91 | 17.7 (14.8–21.2) | 24 | 16.1 (11.4–22.6) | 6 | 19.6 (10.0–38.5) |
Breast cancer | ||||||||||
< 60 | 2144 | Reference | 4 | 1.8 (0.6–5.1) | 18 | 1.9 (1.2–3.0) | 17 | 1.3 (0.8–2.0) | 19 | 0.5 (0.3–0.8) |
60–79 | 5251 | 3.9 (3.7–4.1) | 12 | 9.1 (5.8–14.2) | 36 | 5.6 (4.0–7.7) | 25 | 6.2 (4.3–8.9) | 16 | 7.4 (4.6–12.0) |
≥ 80 | 3641 | 15.7 (14.8–16.6) | 7 | 17.5 (9.3–33.1) | 24 | 23.4 (16.6–32.9) | 12 | 18.1 (10.7–30.6) | 2 | 25.6 (3.07–212.4) |
Prostate cancer | ||||||||||
< 60 | 2144 | Ref | 1 | 1.2 (0.2–9.0) | 9 | 1.2 (0.6–2.4) | 10 | 0.8 (0.4–1.5) | 14 | 0.4 (0.2–0.6) |
60–79 | 5251 | 3.9 (3.7–4.1) | 22 | 5.9 (4.0–8.8) | 139 | 6.4 (5.4–7.6) | 96 | 5.9 (4.9–7.1) | 65 | 7.6 (6.1–9.5) |
≥ 80 | 3641 | 15.8 (14.9–16.7) | 7 | 16.7 (9.3–30.0) | 46 | 17.2 (14.0–21.1) | 13 | 29.3 (17.0–50.5) | 1 | 29.5 (27.4–31.7) |
Colorectal cancer | ||||||||||
< 60 | 2144 | Reference | 2 | 2.8 (0.5–14.8) | 10 | 2.9 (1.6–5.3) | 16 | 2.1 (1.3–3.4) | 22 | 0.7 (0.4–1.0) |
60–79 | 5251 | 3.9 (3.7–4.1) | 24 | 13.3 (8.3–21.5) | 62 | 11.3 (9.0–14.3) | 68 | 13.1 (10.2–16.8) | 39 | 10.4 (7.6–14.3) |
≥ 80 | 3641 | 15.7 (14.8–16.6) | 11 | 17.4 (10.2–29.6) | 46 | 26.5 (18.6–37.7) | 9 | 28.5 (16.0–50.9) | 0 | 0 (0–0) |
Non-Hodgkin lymphoma | ||||||||||
< 60 | 2144 | Reference | 4 | 4.7 (2.4–9.4) | 7 | 1.9 (0.9–4.1) | 1 | 0.2 (0.0–1.1) | 7 | 0.2 (0.1–0.5) |
60–79 | 5251 | 3.9 (3.7–4.1) | 7 | 21.5 (9. 9–46.7) | 42 | 13.9 (10.7–18.1) | 18 | 15.7 (9.1–27.2) | 14 | 13.4 (7.2–24.7) |
≥ 80 | 3641 | 15.67 (14.8–16.6) | 1 | 50.0 (45.9–54.6) | 12 | 27.6 (14.6–51.8) | 0 | 0 | ||
Lung cancer | ||||||||||
< 60 | 2144 | Reference | 5 | 15.3 (6.8–34.5) | 11 | 3.7 (2.0–6.9) | 15 | 2.4 (1.4–4.0) | 32 | 1.1 (0.8–1.6) |
60–79 | 5251 | 3.9 (3.7–4.1) | 16 | 28.7 (16.1–51.2) | 64 | 42.3 (29.3–61.0) | 34 | 35.2 (21.9–56.5) | 31 | 34.6 (25.1–47.6) |
≥ 80 | 3641 | 15.7 (14.8–16.6) | 3 | 56.9 (23.6–136.9) | 7 | 62.5 (36.5–106.9) | 6 | – | 1 | – |
Cancer of unknown primary | ||||||||||
< 60 | 2144 | Reference | 1 | 1.7 (0.2–14.2) | 13 | 4.9 (2.8–8.6) | 13 | 2.2 (1.2–3.7) | 22 | 0.8 (0.5–1.2) |
60–79 | 5251 | 3.9 (3.7–4.1) | 6 | 40.0 (13.7–116.8) | 28 | 35.0 (17.6–69.7) | 22 | 50.0 (32.4–77.1) | 22 | 97.0 (66.3–141.9) |
≥ 80 | 3641 | 15.7 (14.8–16.6) | 3 | 23.8 (9.71–58.2) | 13 | 50.2 (16.2–155.7) | 1 | 231.6 (210.3–255.1) | 1 | 227.0 (206.2–249.8) |